Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy’s GMP Woes Puts Spotlight On Daiichi Sankyo Due Diligence

This article was originally published in PharmAsia News

Executive Summary

Whether Daiichi Sankyo will be able to claim damages from Ranbaxy’s former owners will depend on what Daiichi Sankyo knew before the acquisition, and its chances of proving misrepresentation may be slim.

You may also be interested in...

Are Novartis’ Advertising Charges In Japan The Tip Of The Iceberg?

Prosecutors are looking into allegations of exaggerated advertising, but a bribery investigation may be the real aim for authorities.

HIV Treatment Options For Patients Improve In Japan

Japan Tobacco brings Stribild home after U.S./EU launches by Gilead. Johnson & Johnson reduces patient burden with higher dose Prezista.

Rubella Outbreak Sign Of Japan’s History Of Vaccination Gap; Takeda, Other Domestic Manufacturers Ramp Up Output

Domestic vaccine manufacturers such as Takeda are ramping up production to meet new demand, and MHLW is drafting policies to fill Japan’s rubella vaccination gap.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts